Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$866 Mln
P/E Ratio
--
P/B Ratio
0.73
Industry P/E
--
Debt to Equity
0.08
ROE
-0.38 %
ROCE
-35.32 %
Div. Yield
0 %
Book Value
8.46
EPS
-3.84
CFO
$355.83 Mln
EBITDA
$729.22 Mln
Net Profit
$-229.72 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Vir Biotechnology (VIR)
| -18.53 | -10.75 | -43.53 | -27.34 | -34.82 | -28.82 | -- |
|
BSE Sensex*
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
Vir Biotechnology (VIR)
| -26.85 | -60.25 | -39.55 | 56.35 | 112.96 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.55 | 10,593.45 | 21.84 | 23.13 | |
| 306.35 | 8,570.17 | 22.78 | 66.44 | |
| 27.82 | 10,589.59 | -- | -28.77 | |
| 107.24 | 10,559.67 | 32.44 | 14.16 |
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of... product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California. Address: 1800 Owens Street, San Francisco, CA, United States, 94158 Read more
Executive VP & Chief Technology Officer
Dr. Ann M. Hanly Ph.D.
Executive VP & Chief Technology Officer
Dr. Ann M. Hanly Ph.D.
Headquarters
San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Vir Biotechnology Inc (VIR) stood at $ 1,399 Mln as on 31-Dec-24
The share price of Vir Biotechnology Inc (VIR) is $5.98 (NASDAQ) as of 29-Apr-2025 16:12 EDT. Vir Biotechnology Inc (VIR) has given a return of -34.82% in the last 3 years.
Vir Biotechnology Inc (VIR) has a market capitalisation of $ 866 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Vir Biotechnology Inc (VIR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Vir Biotechnology Inc (VIR) and enter the required number of quantities and click on buy to purchase the shares of Vir Biotechnology Inc (VIR).
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California. Address: 1800 Owens Street, San Francisco, CA, United States, 94158
The CEO & director of Dr. Ann M. Hanly Ph.D.. is Vir Biotechnology Inc (VIR), and CFO & Sr. VP is Dr. Ann M. Hanly Ph.D..
There is no promoter pledging in Vir Biotechnology Inc (VIR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Vir Biotechnology Inc. (VIR) | Ratios |
|---|---|
|
Return on equity(%)
|
-38.09
|
|
Operating margin(%)
|
-744.11
|
|
Net Margin(%)
|
-703.4
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Vir Biotechnology Inc (VIR) was $0 Mln.
$-0.12
(
